Cytodyn Inc (CYDY)

[stockorus]

We really cannot know this, what proportion of initial discharges will be premature.

Your assumption is that patients may get discharged prematurely and later they die when this could have been avoided with more LL doses. The trial as designed places much greater significance to the first outcome of discharge from hospital (for criticals). If early discharge happens for these patients, that is itself to be marked as a success, as something indicating efficacy of the drug if we get SS on this. If patient relapses later, yes it is bad for that patient and bad for some of the SE; but we cannot take those cases to assume that the discharge was unwarranted in the first place. Discharge with SS is big enough result to conclude LL efficacy.